AI Clinical Tools

Allen & Overy Shearman Sterling published guidance on April 14, 2026, addressing data provenance in AI-driven pharmaceutical R&D—a critical issue as drug developers race to cut costs and accelerate timelines. The firm's Q&A examines why datasets must be traceable, compliant, and legally defensible as biotech AI platforms accumulate vast data pools for therapy identification, protein pattern recognition, and clinical optimization. When major pharmaceutical companies acquire these AI capabilities, rigorous due diligence becomes essential to manage legal exposure, privacy violations, and intellectual property disputes.

The law firm Sheppard Mullin released a podcast episode examining artificial intelligence deployment in skilled nursing facilities, with a focus on the "human in the loop" model where AI assists rather than replaces clinical judgment. The episode, part of the firm's "Health-e Law" series hosted by partner Michael D. Orlando, featured Ernie Ianace of CareAlly, which develops AI solutions for post-acute care environments. The discussion centered on how AI can automate administrative and clinical processes—particularly RAI documentation and PDPM coding—while preserving human oversight in decision-making.